Sun K.Y. .2020 .Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020.” Seminars in Arthritis and Rheumatism. , 11 : 175-191.
Dalakas M.C. .2015 .Inflammatory muscle diseases. ” New England Journal of Medicine, 10 : 1734-1747.
Schnabel A. . .Interstitial lung disease in polymyositis and dermatomyositis. Current Rheumatology Reports, 10(2005) : 99-105.
Findlay A.R. .2015 .An overview of polymyositis and dermatomyositis. ” Muscle and Nerve, 10 : 638-656.
Hara M. .2023 .Clinical risk factors for dysphagia and esophageal dysmotility in systemic sclerosis. ” Journal of Clinical Medicine, 10(10) : 3448.
Thoracic American .2002 .multidisciplinary consensus classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine, 10 : 277-304.
Marie I. .2002 .Interstitial lung disease in polymyositis and dermatomyositis. ” Arthritis and Rheumatism, 10 : 614-622.
Fathi M. .2003 .Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. ” Annals of the Rheumatic Diseases, 006122 : 297-301.
Bohan A.,J.B. Peter. A. .1975 .Polymyositis and dermatomyositis: first of two parts. ” New England Journal of Medicine, 10 : 344-347.
Bohan A.,J.B. Peter. A. .1975 .Polymyositis and dermatomyositis: second of two parts. ” New England Journal of Medicine, 10 : 403-407.
Hoppo T. . .Su1529 is idiopathic pulmonary fibrosis really idiopathic?: Patterns of reflux analyzed by bi-positional high-resolution manometry and hypopharyngeal multichannel intraluminal impedance. ” Gastroenterology, 5085(12) : 64096-7.
Njoroge M.W. .2021 .Changing lung function and associated health-related quality-of-life: A five-year cohort study of Malawian adults. ” EClinicalMedicine, 101166 : 101166.
Yang S.H. .2019 .Polymyositis and dermatomyositis - challenges in diagnosis and management. ” Journal of Translational Autoimmunity, 100018(2019) : 100018.
Reddy A. . .-following-dermatomyositis-a-case-linkingdepression-with-inflammation/.. ” Psychopharmacology Bulletin, 48(2018) : 22-28.
Košutova P.,Mikolka P. . .Aspiration syndromes and associated lung injury: incidence, pathophysiology and management. Physiological Research, 10(2021) : S567-S583.
Huang L. . .High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibodypositive dermatomyositis: Experience from a single center. ” Arthritis Research and Therapy, 10(2021) : 232.
Marie I. .2010 .Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Seminars in Arthritis and Rheumatism, 08(2011) : 48-60.
Mastaglia F.L. . .The changing spectrum of drug-induced myopathies. ” Acta Myologica, 10(2020) : 2532-288.
Schiopu E. . .Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: Effect of corticosteroids, methotrexate and azathioprine. Arthritis Research and Therapy, 10(2012) : R22.
Hallowell R.W.,Paik J.J. . .Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. ” Clinical and Experimental Rheumatology, 10(2022) : 373-383.
Marie I. . .Interstitial lung disease in polymyositis and dermatomyositis. ” Arthritis and Rheumatism, 10(2002) : 614-622.
Kim E.J. . .Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. ” Chest, 10(2009) : 0444-1405.
Richter P. .2023 ."Interstitial lung disease in systemic lupus erythematosus and systemic sclerosis: how can we manage the challenge?". International Journal of Molecular Sciences, 10(11) : 9388.
Yunt Z.X.,Solomon J.J. .2014 ."Lung disease in rheumatoid arthritis." Rheumatic Disease Clinics of North America. , 12(2015) : 225-236.
Solomon J.J.,K.K. Brown J.J. . ."Rheumatoid arthritisassociated interstitial lung disease." Open Access Rheumatology. , 10(2012) : 21-31.
Demoruelle M.K. . ."When and where does inflammation begin in rheumatoid arthritis?" Current Opinion in Rheumatology. , 26(2014) : 64-71.
Hunter K.,Lyon M.G. . ."Evaluation and management of polymyositis.". Indian Journal of Dermatology, 10(2012) : 100479-5154.
Angum F. .2020 ."The prevalence of autoimmune disorders in women: a narrative review. " Cureus, 10(5) : .
Misra A.K. . ."Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies." BMC Pulmonary Medicine. , 10(2021) : 370.
Dalakas M.C.,Hohlfed R. .2003 ."Polymyositis and dermatomyositis." The Lancet. , 362 : 971-982.
Mende M. . ."Autoantibodies in myositis: how to achieve a comprehensive strategy for serological testing.". Mediterranean Journal of Rheumatology, 10(2019) : 155-161.
Raychaudhuri S.P.,Mitra A. . ."Polymyositis and dermatomyositis: disease spectrum and classification.". Indian Journal of Dermatology, 10(2012) : 100477-5154.
Park E.H. . ."Raynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis.". International Journal of Rheumatic Diseases, 10(2019) : 13456-185X.
Chen F. .2012 ."Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. " Rheumatology International, 10(12) : 3909-3915.
Moghadam-Kia S. . ."Antimelanoma differentiationassociated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. " Journal of Rheumatology, 10(2017) : 319-325.
De Lorenzo,R. Lorenzo .2018 ."Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. " Neurology, 10(23) : e2068-e2076.
Paik J.J. . ."Muscle disease in scleroderma." Current Opinion in Rheumatology. , 10(2018) : 576-580.
Lega J.C. .2014 ."The clinical phenotype associated with myositis-specific and associated autoantibodies: a metaanalysis revisiting the so-called antisynthetase syndrome. " Autoimmunity Reviews, 03(2014) : 883-891.
Lega J.C. . ."Interstitial lung disease associated with antiPM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?". Journal of Rheumatology, 10(2010) : 1000-1009.
Selva-O'Callaghan A. . ."Myositis-specific and myositisassociated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy." Arthritis and Rheumatism. , 10(2006) : 791-798.
Marie I. .2011 ."Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients." Arthritis and Rheumatism. , 10 : 3439-3447.
Ji S.Y. .2010 ."Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. " Chinese Medical Journal (English), 05 : 6999-522.
Koreeda Y. .2010 ."Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. " Internal Medicine, 10 : 361-369.
Fujisawa T. .2014 ."Prognostic factors for myositis-associated interstitial lung disease. " PLoS One, 0098824 : .
Douglas W.W. .2001 ."Polymyositis-dermatomyositisassociated interstitial lung disease." American Journal of Respiratory and Critical Care Medicine. , 10 : 1182-1185.